Laser ablation technology for destroying breast tumors gets CE Mark approval

July 19, 2019
The approval allows the company to commercialize its laser ablation technology in the European Union and Switzerland, giving women an alternative to surgery for early-stage breast cancer and benign breast tumors.

Novian Health (Chicago, IL) has obtained CE Mark approval for its Novilase Breast Therapy, a minimally invasive laser ablation procedure that uses laser-induced heat for focal destruction of breast tumors up to 2 cm in size. The approval allows the company to commercialize its technology in the European Union (EU) and Switzerland, giving women an alternative to surgery for early-stage breast cancer and benign breast tumors (fibroadenomas).

The minimally invasive laser ablation technology requires only local anesthesia. Two small probes are inserted into the breast and guided to the tumor by ultrasound imagingone probe uses heat to destroy the tumor, while the other monitors the procedure through temperature. The treatment takes less than 30 minutes and its success is confirmed by follow-up imaging. 

A recent study conducted in the U.S. and UK showed that more than 90% of malignant breast tumors were completely destroyed during one Novilase procedure. In addition, patients in the trial reported better health-related quality of life outcomes compared to lumpectomy surgery. No serious adverse events were reported. 

Related: Novian Health begins laser therapy clinical trial for breast cancer

In the U.S., the laser ablation technology has been cleared as an alternative to surgery for the treatment of fibroadenomas. The FDA approved an investigational device exemption (IDE) to conduct a confirmatory study (BR-003) to gather data to support a marketing application for focal destruction of malignant breast tumors. Investigators at U.S. and European sites will participate in the BR-003 study. 

In addition to obtaining the CE Mark approval, the company also received ISO:13485:2016 certification for its quality management system. To earn the certification, the company had to demonstrate its ability to provide its products and related services in a way that consistently meets customer and applicable regulatory requirements. 

For more information, please visit

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)

Sponsored Recommendations

Melles Griot® XPLAN™ CCG Lens Series

March 19, 2024
IDEX Health & Science sets a new standard with our Melles Griot® XPLAN™ CCG Lens Series fluorescence microscope imaging systems. Access superior-quality optics with off-the-shelf...

Spatial Biology

March 19, 2024
Spatial Biology refers to the field that integrates spatial information into biological research, allowing for the study of biological systems in their native spatial context....

Fluorescent Protein Optical Imaging Considerations

March 19, 2024
What factors should you consider when your incorporate fluorescent proteins in an optical imaging application? Learn more.

Custom-Engineered Optical Solutions for Your Application

March 19, 2024
We combine advanced optical design and manufacturing technology, with decades of experience in critical applications, to take you from first designs to ongoing marketplace success...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!